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Abstract
Background: The mortality rate from disseminated intravascular coagulation
(DIC) is higher in patients with lung cancer than in non-lung cancer patients.
Moreover, the prevalence of DIC varies among the pathologic types of lung can-
cer. This study analyzed the relationship between coagulation factors and the
pathologic types of lung cancer.
Methods: Twenty-six patients with progressive, inoperable stage IIB or higher
lung cancer (20 men, 6 women; mean age 71 years; 11 Adeno, 10 squamous cell
carcinoma, and 5 small cell carcinoma) and ﬁve healthy volunteers without respi-
ratory disease (3 men, 2 women; mean age 72 years) were enrolled in the study.
Blood samples were collected at lung cancer diagnosis, before treatment.
Results: White blood cell count, platelet count, serum C-reactive protein, ﬁbrin/
ﬁbrinogen degradation products, ﬁbrinogen, thrombin-antithrombin complex,
and D-dimer levels differed signiﬁcantly between lung cancer patients and the
control group, but not among the pathologic types of lung cancer. Thrombomo-
dulin levels were signiﬁcantly higher in patients with Adeno and squamous cell
carcinoma than in those with small cell carcinoma (P < 0.05 and P < 0.01,
respectively). Antithrombin levels were signiﬁcantly lower in patients with squa-
mous cell carcinoma than in those with Adeno (P < 0.05).
Conclusion: Coagulation disorders may develop secondary to chronic inﬂamma-
tion in patients with progressive lung cancer. DIC in lung cancer may be attrib-
uted to changes in anticoagulation factors, such as thrombomodulin and
antithrombin, but not in other coagulation factors.
Introduction
Lung cancer and other solid tumors are known risk factors
for disseminated intravascular coagulation (DIC), and the
mortality rate among lung cancer patients who develop
DIC is very high.1–3 Several publications have reported the
relationship between better prognosis and increased
thrombomodulin expression in lung cancer, and have sug-
gested that thrombomodulin might inhibit the develop-
ment of DIC.4–6 However, the relationship between
thrombomodulin and DIC in lung cancer patients has not
been evaluated in previous studies.
In our previous study on the relationship between blood
coagulation factors and DIC in patients with lung cancer,
we found that serum C-reactive protein (CRP) level and
prothrombin time-international normalized ratio (PT-INR)
at the onset of DIC were lower in survivors than in
non-survivors.7 These two factors were more sensitive indi-
ces than the DIC score.7,8 When the effects of
thrombomodulin-α therapy for DIC in patients with lung
cancer were analyzed, the required dose of
thrombomodulin-α was higher in survivors than in non-
survivors.7 The percentage of patients with DIC was also
signiﬁcantly lower in squamous cell carcinoma (SCC;
1.57%) than in Adeno (4.23%) and small cell lung carci-
noma (SCLC; 10.26%).7 Other pathologic studies have
shown that thrombomodulin expression was higher in
SCC than in Adeno or other types of lung cancer.4,9 These
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studies suggested that the risk of DIC varies among the
pathologic types of lung cancer.
According to the abovementioned studies, certain blood
coagulation factors, such as PT-INR or thrombomodulin,
may contribute to the development of DIC in patients with
lung cancer and the expression of these coagulation factors
may differ among pathologic types of lung cancer, leading
to differences in the propensity to develop DIC. This study
analyzed the relationship between blood coagulation fac-
tors and pathologic types of lung cancer, with the aim of
preventing DIC in lung cancer.
Methods
Study design
This prospective study enrolled patients who were diagnosed
with but had not yet received treatment for progressive
inoperable stage IIB or higher lung cancer at our hospital
between August 2015 and 2017. The study objective was
explained to the patients and written informed consent was
obtained upon disclosure of their diagnosis and stage.
We also obtained written informed consent from healthy
volunteers. The ethics committee of the Dokkyo Medical
University Koshigaya Hospital (No. 1440) approved the study.
In addition to data on the baseline levels of blood coagu-
lation factors, data on baseline white blood cell (WBC)
count and serum CRP at the time of lung cancer diagnosis
were obtained. The relationship between these blood fac-
tors and the pathologic types of lung cancer was analyzed.
Subjects
Subjects comprised 26 patients (20 men, 6 women; mean
age, 71  6.3 years) diagnosed with lung cancer according
to the criteria speciﬁed by the National Comprehensive
Cancer Network10,11 and ﬁve healthy volunteers without
respiratory disease and malignant tumors (3 men, 2 women;
mean age, 72  4 years) as controls (Table 1). The patho-
logic types of lung cancer were Adeno in 11, SCLC in 5, and
SCC in 10 subjects. The stage of lung cancer was IIB in
2, IIIA in 8, IIIB in 5, and IV in 11 subjects.
Measurement of blood coagulation and
ﬁbrinolysis factors
Fibrin/ﬁbrinogen degradation products (FDP) were mea-
sured by using latex immunoturbidimetric assay. Fibrino-
gen and prothrombin time (PT) were measured by using a
blood coagulation procedure and PT-INR was calculated.
Protein C activity and the level of activated factor VIII was
measured using the automatic hemostasis analyzer ACL
TOP (Instrumentation Laboratory, Bedford, MA, USA).
Thrombomodulin and thrombin-antithrombin complex
(TAT) were measured by enzyme immunoassay using the
Emax Microplate Reader (Molecular Devices LLC, San
Jose, CA, USA). Von Willebrand factor (vWF) antigen was
measured by latex agglutination assay using the automatic
analyzer JCA-BM 1650 (JEOL Ltd., Tokyo, Japan). Plas-
minogen was measured with the chromogenic synthetic
substrate method by using the automatic analyzer JCA-BM
1650 (JEOL Ltd.). D-dimer was measured by latex immu-
noturbidimetric assay. Antithrombin was measured with
the chromogenic synthetic substrate method. Tissue plas-
minogen activator and plasminogen activator inhibitor-1
(tPA/PAI-1) complex was measured with latex photometric
immunoassay using the automatic analyzer, STACIA
(Instrumentation Laboratory).
Statistical analysis
All statistical analyses were performed using Excel
(Microsoft Corporation, Washington, DC, USA) and JMP
(SAS Institute Inc., Cary, NC, USA) software. Differences
between two independent samples were examined by the
chi-square or Wilcoxon’s signed-rank tests, as appropriate.
Differences of P < 0.05 were considered statistically signiﬁ-
cant. No signiﬁcant difference was shown as NS.
Results
Relationship between laboratory data and
pathologic types of lung cancer
The background patient characteristics are shown in
Table 1. Chi-square tests revealed no signiﬁcant differ-
ences between the patients with lung cancer and healthy
Table 1 Background patient characteristics
Characteristic Patients (%) Controls (%)
Subject 26 5
Mean age (years) 71.0  6.3 72.0  4.0
Male/female 20/6 3/2
Smoking
Smoker 12 (46.2) 0 (0.0)
Ex-smoker 11 (42.3) 0 (0.0)
Never-smoker 3 (11.5) 5 (100)
Lung cancer group
Adeno 11 (42.3)
SCC 10 (38.5)
SCLC 5 (19.2)
Stage
II B 2 (7.7)
III A 8 (30.8)
III B 5 (19.2)
IV 11 (42.3)
Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small
cell lung carcinoma.
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controls, with the exception of smoking. WBC count
and serum CRP level were analyzed in each of the path-
ologic type groups at the time of lung cancer diagnosis
and staging and in the controls (Fig 1). No signiﬁcant
differences were noted among the four groups in terms
of the WBC count (Adeno 7.30  1.43 × 103/μL; SCC
7.60  2.13 × 103/μL; SCLC 9.52  5.74 × 103/μL; con-
trols 5.68  1.17 × 103/μL) (Fig 1a). However, the WBC
count was signiﬁcantly higher in all patients with lung
cancer (7.84  2.90 × 103/μL; P < 0.05) and non-small
cell lung cancer (NSCLC) (7.44  1.76 × 103/μL;
P < 0.05) than in the control group.
The serum CRP level was signiﬁcantly higher in patients
with Adeno (2.21  3.46 mg/dL; P < 0.05) and SCC
(1.85  1.87 mg/dL; P < 0.05) than in the control group
(0.14  0.19 mg/dL), but not when compared to patients
with SCLC (1.00  1.78 mg/dL, NS) (Fig 1b). The serum
CRP level was signiﬁcantly higher in all patients with lung
cancer (1.84  2.60 mg/dL; P < 0.05) and NSCLC
(2.04  2.76 mg/dL; P < 0.05) than in the control group.
Relationship between blood coagulation
factors used in the disseminated
intravascular coagulation score and
pathologic types of lung cancer
Platelet count, FDP, ﬁbrinogen, and PT-INR were deter-
mined for the pathologic type groups at the time of lung
cancer diagnosis and staging and for the controls (Fig 2).
The platelet count was signiﬁcantly higher in patients with
Adeno (29.8  10.5 × 104/μL; P < 0.05) and SCC
(32.8  12.1 × 104/μL; P < 0.05) compared to the control
group (19.2  3.5 × 104/μL), but not in patients with
SCLC (29.1  15.3 × 104/μL, NS) (Fig 2a). The platelet
count was signiﬁcantly higher in all patients with lung
cancer (30.8  11.7 × 104/μL; P < 0.05) and NSCLC
(31.2  11.1 × 104/μL; P < 0.05) than in the control group.
The FDP level was signiﬁcantly higher in patients with
Adeno (10.3  11.2 μg/mL; P < 0.05) and SCC
(5.89  5.54 μg/mL; P < 0.05) than in the control group
(2.50  0.51 μg/mL), but not when compared to patients
with SCLC (4.72  1.88 μg/mL, NS) (Fig 2b). The FDP level
was signiﬁcantly higher in all patients with lung cancer
(7.55  8.25 μg/mL; P < 0.05) and NSCLC (8.22  9.05 μg/mL;
P < 0.05) than in the control group.
The ﬁbrinogen level was signiﬁcantly higher in patients
with Adeno (533  173 mg/dL; P < 0.05) and SCC
(521  155 mg/dL; P < 0.05) than in the control group
(314  79 mg/dL), but not when compared to patients
with SCLC (477  150 mg/dL, NS) (Fig 2c). The ﬁbrino-
gen level was signiﬁcantly higher in all patients with lung
cancer (518  157 mg/dL; P < 0.05) and NSCLC
(528  160 mg/dL; P < 0.05) than in the control group.
The difference in PT-INR values was signiﬁcant between
patients with SCC and the control (1.03  0.06
vs. 0.95  0.06, respectively; P < 0.05), but not with the
other groups (Adeno 0.98  0.08, SCLC 1.00  0.08)
(Fig 2d). Moreover, there were no signiﬁcant intergroup
differences in the PT-INR values in all patients with lung
cancer (1.00  0.08) and NSCLC (1.00  0.08).
Relationship of thrombomodulin and
activated protein C with pathologic types
of lung cancer
Thrombomodulin and activated protein C were determined
for the pathologic type groups at the time of lung cancer diag-
nosis and staging and for the controls (Fig 3). Thrombomo-
dulin levels were signiﬁcantly higher in patients with Adeno
(2.94  0.53 FU/ml; P < 0.05), SCC (3.93  2.80 FU/mL;
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Figure 1 (a) White blood cell (WBC) count and (b) serum C reactive protein (CRP) level differ signiﬁcantly between lung cancer patients and controls, but
not among the pathologic types of lung cancer. *P < 0.05. Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
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P < 0.01), and NSCLC (3.41  1.98 FU/mL; P < 0.01) than
in those with SCLC (2.24  0.21 FU/mL) (Fig 3a). The
thrombomodulin level was signiﬁcantly higher in patients
with NSCLC compared to the control (2.30  0.71 FU/mL;
P < 0.05), but not when compared to all patients with lung
cancer (3.18  1.84 FU/mL, NS).
The were no signiﬁcant intergroup differences in the level
of activated protein C (Adeno 107.7  25.7%, SCC
95.9  22.4%, SCLC 99.2  20.9%, and control,
108.4  17.0%) or between all patients with lung cancer
(101.5  23.4%) and NSCLC (102.1  24.4%) (Fig 3b).
Relationship of other blood coagulation
factors as activated factor VIII, vWF
antigen, and TAT with pathologic types of
lung cancer
Those levels of activated factor VIII, vWF antigen, and
TAT, are shown in Figure 2. There were no signiﬁcant
intergroup differences in activated factor VIII levels among
patients with Adeno (129  33%), SCC (115  16%), SCLC
(135  50%), and in the control (116  18%) or between
all patients with lung cancer (125  31%) and those with
NSCLC (122  26%) (Fig 4a).
There were no signiﬁcant intergroup differences in the
vWF antigen level among patients with Adeno
(178  54%), SCC (167  70%), SCLC (202  85%), and
in the control (130  33%) or between all patients with
lung cancer (179  65%) and those with NSCLC
(173  61%) (Fig 4b).
The TAT level was signiﬁcantly higher in patients with
lung cancer (Adeno 3.43  1.77 ng/mL, P < 0.05; SCC
7.32  6.78 ng/mL, P < 0.05; and SCLC 3.54  0.90 ng/
mL, P < 0.05) than in the control group (1.52  0.43 ng/
mL) (Fig 4c). The TAT level was also signiﬁcantly higher
in all patients with lung cancer (4.95  4.65 ng/mL;
P < 0.01) and in those with NSCLC (5.28  5.12 ng/mL;
P < 0.05) than in the control.
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Figure 2 (a) Platelet count, (b) ﬁbrin/ﬁbrinogen degradation products (FDP), and (c) ﬁbrinogen are signiﬁcantly different between lung cancer
patients and the control, but not among the pathologic types of lung cancer. (d) There were no signiﬁcant differences in prothrombin time-
international normalized ratio (PT-INR). *P < 0.05. Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
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Relationship between blood ﬁbrinolysis
factors and pathologic types of lung
cancer
Those levels of plasminogen and D-dimer are shown in
Figure 5. There were no signiﬁcant intergroup differences
in plasminogen level among patients with Adeno
(114  14%), SCC (112  16%), SCLC (100  23%), and
the control (108  8%) or between all patients with lung
cancer (111  17%) and NSCLC (113  15%) (Fig 5a).
The difference in D-dimer values was only signiﬁcant
between patients with Adeno and the control
(3.70  4.21 μg/mL vs. 0.67  0.08 μg/mL; P < 0.05), and
not with the other groups (SCC 2.08  2.56 μg/mL, SCLC
1.63  0.80 μg/mL) (Fig 5b). Moreover, the D-dimer
values were signiﬁcantly higher in all patients with lung
cancer (2.68  3.22 μg/mL; P < 0.05) and NSCLC
(2.93  3.54 μg/mL; P < 0.05) than in the control.
Relationship of anticoagulation and/or
ﬁbrinolysis factors with pathologic types
of lung cancer
Those levels of antithrombin and tPA/PAI-1 complex were
determined for the pathologic type groups at the time of
lung cancer diagnosis and staging and the controls (Fig 6).
The antithrombin level was signiﬁcantly lower in patients
with SCC than in those with Adeno (95.7  11.7%
vs. 111.4  15.4%; P < 0.05), but no signiﬁcant differences
were observed in the other groups (SCLC 104.4  7.1%,
control 99.2  13.6%) (Fig 6a). The antithrombin level
was not signiﬁcantly different between all patients with
lung cancer (104.0  14.3%) and NSCLC (103.9  15.7%).
There were no signiﬁcant intergroup differences in
tPA/PAI-1 complex level among patients with Adeno
(21.2  10.9 ng/mL), SCC (20.4  4.8 ng/mL), SCLC
(26.0  13.5 ng/mL), and the control (29.6  12.9 ng/mL)
or between all patients with lung cancer
(21.8  9.4 ng/mL) and NSCLC (20.8  8.3 ng/mL)
(Fig 6b).
Discussion
This study demonstrates that patients with lung cancer had
higher WBC count, CRP level, and blood coagulation and
ﬁbrinolysis parameters, including platelet count, FDP,
ﬁbrinogen, thrombomodulin, TAT, and D-dimer, com-
pared to healthy volunteers. Comparison of the pathologic
types showed signiﬁcantly higher thrombomodulin levels
in Adeno and SCC than in SCLC and a signiﬁcantly lower
antithrombin level in SCC than in Adeno.
Interleukin (IL-6) is known to induce CRP 6, and IL-6
and CRP levels are reported to be higher in individuals
with lung cancer than in those with benign respiratory dis-
ease.11 One mechanism could be the fact that lung cancer
cells produce IL-6.12,13 Changes in IL-6 levels have been
used to estimate the effect of lung cancer treatment.14,15 In
this case, the chronic inﬂammation is caused by lung can-
cer itself. Conversely, in bacterial infection, macrophage
stimulation by bacteria triggers the secretion of IL-6,
resulting in an elevated CRP level. Thus, the risk of DIC is
higher in lung cancer, as in bacterial infection, because
chronic inﬂammation via IL-6 is similar to that induced by
bacterial infection.
In this study, most of the coagulation and ﬁbrinolysis fac-
tors showed abnormal levels in patients with lung cancer
compared to the control. These disorders of coagulation
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Figure 3 (a) Thrombomodulin (TM) levels are signiﬁcantly higher in adenocarcinoma (Adeno) and squamous cell carcinoma (SCC) than in small cell
lung carcinoma (SCLC). (b) No signiﬁcant differences in activated protein C levels were noted among the pathologic types of lung cancer. *P < 0.05;
**P < 0.01. Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
Thoracic Cancer (2018) © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 5
K. Nakano et al. Risk factors for DIC with lung cancer
050
100
150
200
250
A
ct
iv
at
ed
 fa
ct
or
 V
III
 (
%
)
0
50
100
150
200
250
300
350
400
vW
F
 a
nt
ig
en
 (
%
)
ControlAdeno SCC SCLC
ControlAdeno SCC SCLC
ControlAdeno SCC SCLC
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
*
*
*
*
**
T
A
T
 (
ng
/m
l)
a b
c
Figure 4 Comparison between lung cancer patients and controls shows no signiﬁcant differences in levels of (a) activated factor VIII and (b) von
Willebrand factor (vWF) antigen, but a signiﬁcant difference was observed in the (c) thrombin-antithrombin complex (TAT) level. *P < 0.05;
**P < 0.01. Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
0
2
4
6
8
10
12
14
16
18
D
-d
im
er
 (
μg
/m
l)
*
*
*
0
20
40
60
80
100
120
140
160
180
P
la
sm
in
og
en
 (
%
)
a b
ControlAdeno SCC SCLCControlAdeno SCC SCLC
Figure 5 Comparison between lung cancer patients and the control group showing that (a) plasminogen does not signiﬁcantly differ, but the (b) D-
dimer is signiﬁcantly different. *P < 0.05. Adeno, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
6 Thoracic Cancer (2018) © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
Risk factors for DIC with lung cancer K. Nakano et al.
leading to DIC in lung cancer might be attributed to the fact
that chronic inﬂammation increases thrombin production,
which is reﬂected in TAT levels. Another mechanism for
increased thrombin production in lung cancer could be acti-
vation of the X factor by elevated cancer procoagulant level,
which may affect the coagulation system16 however, we did
not evaluate cancer procoagulant in this study. Nevertheless,
elevated thrombin levels from chronic inﬂammation in lung
cancer increases ﬁbrinogen and ﬁbrin levels, which pro-
motes the production of FDP and D-dimer. Therefore,
patients with lung cancer are at risk of developing DIC. In
this study, however, differences in coagulation disorders
were not observed among the pathologic types of lung
cancer.
Thrombomodulin and antithrombin, both anticoagulant
factors in the coagulation pathway, were increased in
patients with Adeno and SCC. Pathological studies have
shown that thrombomodulin expression is higher in SCC
than in Adeno or other types of lung cancer.4,9 The throm-
bomodulin level may be affected by the production of the
lung cancer cells. In our study, the thrombomodulin level
in SCC was signiﬁcantly higher than in SCLC. In our pre-
vious study, the rates of DIC among patients with lung
cancer were 1.57% for SCC, 4.23% for Adeno, and 10.26%
for SCLC, and a negative correlation between the thrombo-
modulin level and the rate of DIC was demonstrated
according to the type of lung cancer.17 Furthermore, the
percentage of lung cancer patients with thrombomodulin-
positive was higher in those with stage IV metastatic can-
cer than in those with stage I–IIIB localized Adeno. In
addition, thrombomodulin expression is reported to be
higher in mesothelioma than in Adeno18,19 and has been
shown to inﬂuence the prognosis of lung cancer, with
thrombomodulin-negative lung cancer yielding a poorer
prognosis than thrombomodulin-positive lung cancer of
the same stage.4,5,20 Therefore, pathologic examination of
thrombomodulin expression may help to assess the prog-
nosis of patients with lung cancer. The presence of throm-
bomodulin suppresses lung cancer cell growth21 and has
been associated with pulmonary toxicity secondary to early
phase radiation for lung cancer.22 Therefore, thrombomo-
dulin has several effects in lung cancer. Thrombomodulin
binds to thrombin, thereby downregulating the procoagu-
lant activity of thrombin. This thrombin-thrombomodulin
complex activates protein C, which normalizes the coagula-
tion system. Therefore, we expected that protein C levels,
similar to the thrombomodulin levels, would be different
among the various types of lung cancer. However, the pro-
tein C levels did not show signiﬁcant differences among
the types of lung cancer in this study. In addition, the
mechanism for the higher thrombomodulin level in SCC
remains unclear.
The higher thrombomodulin levels in SCC and Adeno
observed in this study support our former study, in which
the prevalence of DIC in patients with lung cancer was
lower in SCC and Adeno.7 The risk of DIC can be pre-
dicted from the thrombomodulin level in patients with
lung cancer. When a patient with lung cancer develops
DIC, the best treatment may be to administer human
recombinant thrombomodulin-α.
Patients with progressive lung cancer were observed to
have coagulation disorders, which can likely be attributed
to the elevation of CRP secondary to chronic inﬂammation.
However, no differences in coagulation and ﬁbrinolysis fac-
tors were observed among the pathologic types of lung can-
cer. On the other hand, the thrombomodulin level, which is
an anticoagulation factor, was higher in SCC and Adeno.
Furthermore, the risk of DIC in lung cancer may depend
on the level of thrombomodulin, but not on other coagula-
tion and ﬁbrinolysis factors. Our results suggest that
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evaluation of the thrombomodulin level could predict the
risk of DIC and that human recombinant
thrombomodulin-α might be an effective treatment for DIC
in lung cancer.
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